Roche reached a potential $1.53 billion license deal for SIM-0600, a preclinical CD79a/CD19/CD3 trispecific T-cell engager from Simcere Zaiming Pharmaceutical. The agreement reflects Roche’s strategy to fill gaps in its B-cell disease franchise with next-generation immune cell redirecting formats. Under the terms, Roche gains rights to develop and commercialize the asset, with financial consideration structured around milestones and potential additional payments. The choice of a preclinical trispecific format targets B-cell antigens while directing T cells through CD3 engagement. If the program progresses successfully, it would strengthen Roche’s pipeline in a competitive space where multiple companies are pushing for differentiated TCE constructs and improved tolerability.